Capricor Therapeutics, Inc. (CAPR)
7.59
+0.06
(+0.80%)
USD |
NASDAQ |
Nov 20, 16:00
1.64
-5.95
(-78.39%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (TTM) : 107.50M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 107.50M |
| June 30, 2026 | 98.66M |
| March 31, 2026 | 91.90M |
| December 31, 2025 | 83.50M |
| September 30, 2025 | 74.99M |
| June 30, 2025 | 66.48M |
| March 31, 2025 | 56.97M |
| December 31, 2024 | 49.19M |
| September 30, 2024 | 44.61M |
| June 30, 2024 | 42.86M |
| March 31, 2024 | 39.38M |
| December 31, 2023 | 36.12M |
| September 30, 2023 | 32.58M |
| June 30, 2023 | 28.22M |
| March 31, 2023 | 24.36M |
| December 31, 2022 | 21.82M |
| September 30, 2022 | 19.85M |
| June 30, 2022 | 16.86M |
| March 31, 2022 | 15.39M |
| December 31, 2021 | 13.57M |
| September 30, 2021 | 12.05M |
| June 30, 2021 | 12.17M |
| March 31, 2021 | 10.60M |
| December 31, 2020 | 8.457M |
| September 30, 2020 | 6.541M |
| Date | Value |
|---|---|
| June 30, 2020 | 4.769M |
| March 31, 2020 | 4.486M |
| December 31, 2019 | 5.142M |
| September 30, 2019 | 7.162M |
| June 30, 2019 | 9.437M |
| March 31, 2019 | 11.18M |
| December 31, 2018 | 12.07M |
| September 30, 2018 | 11.74M |
| June 30, 2018 | 10.47M |
| March 31, 2018 | 10.21M |
| December 31, 2017 | 10.77M |
| September 30, 2017 | 10.91M |
| June 30, 2017 | 13.78M |
| March 31, 2017 | 14.96M |
| December 31, 2016 | 16.04M |
| September 30, 2016 | 16.71M |
| June 30, 2016 | 15.17M |
| March 31, 2016 | 14.29M |
| December 31, 2015 | 13.76M |
| September 30, 2015 | 13.01M |
| June 30, 2015 | 11.78M |
| March 31, 2015 | 10.21M |
| December 31, 2014 | 7.782M |
| September 30, 2014 | 10.27M |
| June 30, 2014 | 8.329M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.559B |
| Regeneron Pharmaceuticals, Inc. | 6.083B |
| REGENXBIO, Inc. | 219.05M |
| ARS Pharmaceuticals, Inc. | 30.74M |
| Sionna Therapeutics, Inc. | 74.32M |